Weight Loss
Conditions
Keywords
green tea, weight, women
Brief summary
The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.
Detailed description
Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.
Interventions
DRUGPhosphoLean
Sponsors
Chemi Nutra
The Cooper Institute
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen
Exclusion criteria
* pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight Loss | — |
| Appetite Suppression | — |
Countries
United States
Outcome results
None listed